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ABSTRACT
Introduction: Although depression is often
associated with poor glycemic control in
patients with type 2 diabetes mellitus (T2DM),
this observation has been inconsistent. This
exploratory, post hoc analysis investigated
associations between depression parameters
and glycemic control using data from a
24-month, prospective, observational, non-
interventional study evaluating glycemic
response following insulin initiation for T2DM.
Methods: We analyzed data from a 24-month,
prospective, observational study that evaluated
glycemic response in patients with T2DM who
initiated insulin therapy (N = 985) in 5
European countries. Secondary measures
included patient-reported diagnosis of
depression at baseline, severity of depressed/
anxious mood (EuroQol (EQ)-5D item) and
diabetes-related distress (Psychological Distress
domain of the Diabetes Health Profile, DHP-18).
The latter two measures were assessed at
baseline and 5 time points throughout the
study. Glycemic control was measured by
glycated hemoglobin (HbA1c) at these same
time points. Analyses employed t tests to assess
the unadjusted baseline difference in HbA1c
between patients with and without the
respective depression parameter. The potential
effect of demographic and clinical confounding
variables was controlled through a linear model
structure. Patient HbA1c levels were analyzed by
presence/absence of a history of diagnosed
depression, depressed mood, and diabetes-
related distress.
Results: Patients with higher depression
parameters or distress at baseline had
significantly higher rates of microvascular
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complications at baseline. Patients with a history
of diagnosed depression or high diabetes-related
distress had higher HbA1c than patients without.
HbA1c of patients with or without depressed
mood was not significantly different at baseline.
The proportion of patients with depressed mood
declined after insulin initiation, whereas the
proportion of patients with high diabetes-
related distress did not significantly change.
HbA1c improved following insulin initiation,
regardless of presence/absence of studied
depression/distress parameters at baseline.
Conclusion: History of diagnosed depression,
diabetes-related distress, and depressed mood
were associated with a higher rate of
microvascular complications. Diagnosed
depression and diabetes-related distress also
showed higher HbA1c at baseline when insulin
was initiated. Insulin therapy improved
glycemic control, while preexisting depressed
mood declined and diabetes-related distress
remained unchanged.
Keywords: Depressed mood; Depression;
Diabetes distress; Glycemic control; Insulin
therapy
INTRODUCTION
Depression affects approximately 20–25% of
patients with diabetes [1], with rates of major
depressive disorder estimated at 12% and
depressive symptoms at 15–35% [2]. The
presence of depressive symptoms is associated
with a poorer quality of life in patients with
diabetes and has been shown to be associated
with poorer glycemic control and diabetes
complications [3–7]. Similar associations have
been reported with subthreshold depression [7].
The relationship between glycemic control
and depression is likely bidirectional, but the
causal pathways remain incompletely
understood [8]. Although poorer self-care
among diabetes patients (e.g., adherence to
lifestyle recommendations and glucose
monitoring) is regarded as a potential
contributor to poor glycemic control over
time, it cannot fully account for poor control,
as depression may also impact stress pathways
which in turn can affect glycated hemoglobin
(HbA1c) levels [9, 10]. However, interventions
aimed at reducing depression among patients
with diabetes have not led to the reduction in
HbA1c or improvements in self-care behaviors,
and conversely, an intervention trial to improve
diabetes self-care and glycemic control in
elderly patients with diabetes did not lead to
reduction in depression [11, 12].
Although major depressive disorder and
depressive symptoms have generally been
considered to be associated with poor glycemic
control in type 2 diabetes mellitus (T2DM), the
available data from cross-sectional studies on
this association are inconsistent and
methodological approaches vary across studies
[2, 9, 13–25].
Diabetes-related distress refers to the
emotional burden that may be an aspect of
managing a chronic illness, and can be found in
both those with diabetes and their caregivers
[26]. It is different from the clinical experience
of depression [27–30], as it may manifest more
in emotional reactions to diabetes and its
treatment. High levels of distress have been
significantly linked to elevated HbA1c [29, 31].
Importantly, a prospective, observational, non-
interventional study by Fisher and colleagues
[8] concluded that diabetes distress, but not
clinical depression or depressive symptoms, is
associated with poorer glycemic control in both
cross-sectional and longitudinal analyses. That
18-month study included a relatively
homogeneous group of patients with T2DM
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who participated in diabetes education
programs and had a reasonable level of
glycemic control (average HbA1c of 7.2%). It is
important to replicate these findings in a more
heterogeneous group of patients to fully
understand the relationships between affective
parameters and glycemic control in patients
with T2DM. It is also important to study the
association between HbA1c and depression or
distress parameters prior to and following
patients’ transition to insulin therapy. Barriers
to timely intensification of treatment to insulin
therapy in patients with poor glycemic control
also encompass patients’ psychological insulin
resistance [32, 33], which contributes to long
delays in the start of insulin therapy [34–37].
Psychological resistance to insulin is a
multifaceted, encompassing fear of insulin and
the potential side effects of hypoglycemia and
weight gain, complexity of insulin treatment
and regimens, need to self-monitor blood
glucose to adapt doses, and emotional factors
such as anxiety or depression symptoms
[32, 33, 38–41].
Inconsistencies in our understanding
regarding the link between glycemic control and
depressionmay be due, in part, to the reliance on
diverse measures of depression. These include a
previous depression diagnosis (either from claims
data, medical records, or self-reported), results
from depression diagnostic screening tools (e.g.,
the Center for Epidemiologic Studies-Depression
scale, the Patient Health Questionnaire) or full
batteries, e.g., the Structured Clinical Interview
for DSM-IV [Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition] Diagnosis, scores
from clinical assessments of depression
symptoms (e.g., the Quick Inventory of
Depressive Symptomatology, the Montgomery–
Asberg Depression Rating Scale) or measures of
diabetes-relateddistress [27, 42].A report fromthe
National Institute of Diabetes, Digestive and
Kidney Diseases on diabetes and depression
points out that the definition of depression
varies across studies due to the variability of
measurement and use of undefined terminology
[43].
To help clarify the link between glycemic
control and depression, this study investigated
the association between three types of
depression/diabetes distress parameters
(depression diagnosis, depressed mood, and
diabetes-related distress) over 24 months in
patients with T2DM initiating insulin in a
large, observational, non-interventional trial.
METHODS
Data from the TREAT study [44] were utilized to
conduct an exploratory, post hoc analysis of the
association between depression and glycemic
control over 24 months in patients with T2DM
initiating insulin treatment. The TREAT study
was a 24-month, prospective, observational,
non-interventional study that evaluated
glycemic response in patients with T2DM who
were initiated on insulin therapy (N = 985) in
five European countries (Greece, Portugal,
Romania, Sweden, and Turkey). Insulin-naive
patients with T2DM who presented within the
normal course of care and initiated insulin
under the investigator’s supervision or that of
a referred physician were enrolled. Enrolled
patients at each site had characteristics typical
of patient demographics and physician
specialty (primary care or specialist) for each
country. Further details of the study design and
clinical outcomes are available in the primary
publication [44].
The TREAT study included secondary
measures that are pertinent to depression and
distress, including a history of diagnosis of
depression, severity of depressed/anxious
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mood (EuroQol [EQ]-5D item, hereafter referred
to as ‘‘depressed mood’’), and diabetes-related
distress (Psychological Distress domain of the
Diabetes Health Profile [DHP-18]). The latter
two patient-reported measures were assessed at
baseline and five time points thereafter (3, 6, 12,
18, and 24 months) along with HbA1c, thus
enabling a cross-sectional and longitudinal
evaluation of the potential link between
glycemic control, depressive mood, history of
diagnosed depression, and diabetes-related
distress. Using these three proxy measures of
depression/distress the current study assessed:
(1) at the time of insulin initiation (cross
sectionally), whether depression is associated
with higher HbA1c values; (2) during the
24 months following insulin initiation
(longitudinally), whether depression is
associated with higher HbA1c values; and (3)
the relationships between the three studied
proxy measures of depression/distress.
This analysis evaluated depression in three
ways:
1. History of depression diagnosis—a history
of depression diagnosis was recorded by the
investigator at baseline (‘‘Has the patient
ever been diagnosed with any significant
diagnosis other than diabetes:
depression?’’).
2. Depressed mood—severity of depressed
mood was assessed per patient self-report
on the EQ-5D depression/anxiety item (‘‘I
am not anxious or depressed.’’; ‘‘I am
moderately anxious or depressed.’’; ‘‘I am
extremely anxious or depressed.’’) scored as
0 (not), 1 (moderately), or 2 (extremely).
Presence of depressed mood was defined as
a score of 1 or 2.
3. Diabetes distress—diabetes-related distress
was assessed by the Psychological Distress
domain of the DHP-18, which included six
items that asked the patients about the
impact of diabetes on their mood (e.g.,
getting depressed, losing temper, or
becoming upset, argumentative or moody),
with each item being scored as 0 (never), 1
(sometimes), 2 (often), or 3 (very often).
Patient characteristics, use of oral glucose-
lowering medications, and diabetes disease
history over the previous 12 months were
recorded at baseline along with the presence
of microvascular complications (diabetic
retinopathy, diabetic nephropathy, diabetic
neuropathy, erectile dysfunction, and
amputation) and macrovascular complications
(coronary heart disease, previous myocardial
infract, stroke, transient ischemic attack,
peripheral arterial occlusive disease, chronic
heart failure, and previous coronary artery
bypass graft). Insulin type at initiation was
defined as long/intermediate only, mixture
only, basal/bolus, or short acting only.
Two-sample t tests and Fisher’s exact test were
used to compare baseline patient characteristics.
Group comparisons on HbA1c were performed
with two-sample t tests at each time point
(unadjusted analysis). An adjusted analysis was
alsoperformed toadjust for the effect of potential
confounding variables and estimate the
association that would be seen should the
comparison groups (depressed vs. not
depressed) be at the same level for the adjusted
covariates. For depressed mood and diabetes
distress, group comparisons for HbA1c were
performed using analysis of covariance at each
time point to control for the potential
confounding effect of age, gender, body mass
index (BMI), education, duration of diabetes,
initiated insulin type, and microvascular and
macrovascular complications. For comparison of
HbA1c between groups with and without a
history of diagnosed depression, a longitudinal,
likelihood-based repeated measures mixed
model analysis was used, controlling for age,
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gender, BMI, education, duration of diabetes,
initiated insulin type, and microvascular and
macrovascular complications. Analyses were
exploratory in that they were not planned as
part of the analyses supporting the original
publication for this study. However, the
analyses and the hypotheses they address were
planned and prespecified prior to their being
conducted. Results for all analyses were
considered statistically significant for p\0.05.
SAS version 9.2 (Cary, NC, USA) was used for all
analyses.
Compliance with Ethics
Within the TREAT study, all treatment decisions
were made between the physician and patient,
and care was provided at the discretion of the
physician and according to local standards of
medical care. All patients provided written
informed consent according to local regulations.
Local requirements for ethical review and
regulatory notifications, as appropriate, were
met for each participating country.
The present article does not contain any new
studies with human subjects performed by the
authors.
RESULTS
A total of 985 patients were enrolled with a
mean age of 60.39 years, mean HbA1c 9.55%,
and mean duration of 9.96 years since diagnosis
of T2DM. Overall, 50.1% of patients were
initiated on long/intermediate insulin, 39.3%
on mixtures, 7.8% on basal/bolus regimens, and
2.8% on short-acting insulin. Patient
characteristics at baseline are summarized in
Table 1. Depressed mood was reported by 49.9%
of patients (43.9% moderate, 6.1% severe) and
history of depression diagnosis by 12.4%. Using
the cut-point of those with scores C75th
percentile of the distribution on the DHP-18,
29.9% of patients reported high levels of
diabetes-related distress at baseline.
Table 1 also shows that regardless of the
depression parameter, patients with depressive
symptoms were significantly more likely than
patients without the depression parameter to be
female, to have a higher BMI, and to have
microvascular complications. In addition,
patients with depressed mood had a
significantly longer duration of diabetes than
patients without depressed mood.
Most study participants (752; 76.3%) have
completed the 24-month study. Reasons for
discontinuations (n; %) included: lost to follow-
up (70; 7.1%); physician decision (70; 7.1%);
subject decision (63; 6.4%); death (22; 2.2%);
missing (7; 0.7%); and sponsor decision (2;
0.2%). Using a comparative analysis stratified by
country, the 752 study completers were not
found to significantly differ from the 234 study
dropouts on any of the studied baseline
characteristics. There was, however, one
baseline characteristic with a marginally
significant difference between the completers
and dropouts. There were a lower percentage of
dropouts with a history of depression diagnosis
at baseline compared to study completers.
(9.2% vs. 13.9%, p = 0.054).
Cross-Sectional Analysis at Baseline
HbA1c was significantly (adjusted and
unadjusted, p B 0.001) higher in patients with
a history of diagnosed depression than in
patients without (10.77% vs. 9.36%). HbA1c
was similar in patients with depressed mood
compared to those without depressed mood
(Table 1). HbA1c was significantly higher
(unadjusted, p B 0.001) in patients with high
diabetes distress compared to patients with low
distress (9.91% vs. 9.39%). Differences were not
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statistically significant in the adjusted analysis
(p = 0.701).
Longitudinal Analysis
The proportion of patients with depressed
mood declined over time (from 49.9% to
37.0%, p\0.001; Fig. 1a), while the proportion
of patients with high diabetes distress did not
decline significantly over time (from 29.9% to
26.7%, p = 0.098; Fig. 1b).
Over the 24 months following insulin
initiation, glycemic control (as measured by
mean HbA1c) improved, regardless of the
presence or absence of depression defined by
each parameter as shown in Fig. 2. Patients with
a history of diagnosed depression had
significantly higher HbA1c values during the
first 6 months following insulin initiation
(HbA1c values decreased over time from
Fig. 2 a Mean HbA1c over 24 months by history of
diagnosed depression at baseline. Presented results are from
the unadjusted analysis. Results from the adjusted analysis
showed a similar pattern as the unadjusted analysis. Group
differences were, however, no longer statistically signiﬁcant
at 6 months and became signiﬁcant in the opposite
direction at 18 and 24 months. b Mean HbA1c over
24 months by depressed mood. Presented results are from
the unadjusted analysis. Results from the adjusted analysis
showed the same pattern as the unadjusted analysis. Group
differences were, however, no longer statistically signiﬁcant
at 3 and 6 months. c Mean HbA1c over 24 months by
diabetes distress. High diabetes distress is deﬁned as a score
C75th percentile on the DHP-18 Psychological Distress
domain score at each assessment. Results are presented
from the unadjusted analysis. Results from the adjusted
analysis showed the same pattern as the unadjusted
analysis. Group differences were, however, no longer
statistically signiﬁcant at baseline. DHP-18 Psychological
Distress domain of the Diabetes Health Proﬁle, HbA1c
glycated hemoglobin. *Signiﬁcant difference between the
groups with vs. without the depression parameter at
p B 0.05. **Signiﬁcant difference between the groups with
vs. without the depression parameter at p B 0.01.
***Signiﬁcant difference between the groups with
vs. without the depression parameter at p B 0.001.
D = Difference between groups
Fig. 1 a Decline over time in proportion of patients with
depressed mood [p\0.001 for linear trend test by
Generalized Estimating Equation (GEE)]. b No signiﬁcant
change over time (p = 0.098 for linear trend test by GEE)
in proportion of patients with high diabetes distress
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10.77% to 8.22%) than those without a history
of diagnosis (HbA1c values decreased from
9.36% to 7.74%) (unadjusted p\0.01; Fig. 2a),
but not at subsequent time points (12 months,
p = 0.078; 18 months, p = 0.872; 24 months,
p = 0.193). Over the 24 months, patients with
depressed mood continued to have higher
HbA1c (HbA1c values decreased from 9.62% to
7.79%) compared to patients without depressed
mood (HbA1c values decreased from 9.48% to
7.45%) (unadjusted p B 0.01; Fig. 2b). Higher
HbA1c values were consistently observed in
patients with high diabetes distress (HbA1c
values decreased from 9.91% to 7.90%)
compared to patient without high diabetes
distress (HbA1c values decreased from 9.39%
to 7.48%) throughout the study period
(unadjusted p\0.001; Fig. 2c). Results from




Table 2 presents the correlations between the
three depression and distress parameters over
the 24 months following insulin initiation. The
three measures were positively and significantly
correlated at baseline, although the magnitude
of the associations was relatively low, with the
higher correlation observed between depressed
mood and diabetes distress (r = 0.396). Figure 3




Depressed mood and history of
diagnosed depression
0.194 (p\0.001)a
Depressed mood and diabetes
distress
0.396 (p\0.001)b





Fig. 3 a Depressed mood scores over 24 months by
history of depression diagnosis at baseline. Results are
presented from the unadjusted analysis. Results from the
adjusted analysis showed the same pattern as the unad-
justed analysis. Group differences were, however, no longer
statistically signiﬁcant at 12 months. b Diabetes distress
scores over 24 months by history of depression diagnosis at
baseline. Results are presented from the unadjusted
analysis. Results from the adjusted analysis showed the
same pattern as the unadjusted analysis. Group differences
were, however, no longer statistically signiﬁcant at baseline.
c Depressed mood scores over 24 months by diabetes
distress. Results are presented from the unadjusted analysis.
Results from the adjusted analysis showed the same pattern
as the unadjusted analysis. *Signiﬁcant difference between
the groups with vs. without the depression parameter at
p B 0.05. **Signiﬁcant difference between the groups with
vs. without the depression parameter at p B 0.01. ***Sig-
niﬁcant difference between the groups with vs. without the
depression parameter at p B 0.001. D = Difference
between groups
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shows the longitudinal relationships between
thedepressionparameters. In the first 12 months
post-initiation of insulin therapy, patients with a
history of diagnosed depressionhad significantly
highermean scores on the depressivemood item
compared to patients without a history of
diagnosed depression (Fig. 3a). Similarly, Fig. 3b
and c shows relationships between diabetes
distress and history of diagnosed depression,
and depressed mood by baseline diabetes-
related distress. In all cases, the presence of
depression at baseline is associated with the
presence of more symptoms over time. Results
from the adjusted analysis showed essentially the
same pattern (results not shown).
Sensitivity Analyses
As study participants were enrolled from five
European countries (Greece, Portugal, Romania,
Sweden, and Turkey), we also assessed—as a
sensitivity analysis—the potential impact of
country on the current results by repeating the
original analyses in two ways: we first
reanalyzed the findings while stratifying by
country and then repeated the original
analysis while adding country to the covariates
in the model. Results (not shown) were
essentially unchanged when stratifying by
country and when adding country to the
covariate list. There were, however, four
changes from the original p values (out of 36
new comparisons): two previously significant
comparisons became non-significant and two
previously non-significant comparisons became
significant.
DISCUSSION
This exploratory, post hoc analysis found
consistent and significant associations between
poorer glycemic control and each of the three
depression and distress parameters: history of
depression diagnosis, depressed mood, and
diabetes distress in T2DM patients who
initiated insulin therapy. This analysis also
demonstrated that patients with higher
depression parameters or distress at baseline
had significantly higher rates of microvascular
complications. Poor glycemic control has
indeed been associated with development of
diabetic complications [45], and these
complications are probably a more direct cause
of depressive mood in patients with higher
HbA1c than HbA1c alone. In addition, these
results show that initiation of insulin therapy
was associated with improved glycemic control,
and the proportion of patients with preexisting
depressed mood decreased significantly (by 13%
overall from 49.9% to 37.0%) and resulted in
numerically, but not statistically significant,
reductions in the proportion of patients with
preexisting high diabetes distress (from 29.9%
to 26.7%, p = 0.098).
Consistent with prior research, a substantial
proportion of patients with T2DM in this cohort
were experiencing depression or emotional
distress, as measured by the three proxy
measures of depression. History of depression
diagnosis was present in 12.4% of the patients, a
finding congruent with previous studies that
estimated the prevalence of major depression in
diabetes to be around 12% (ranging from 8% to
18%) [2, 46, 47]. Depressed mood was reported
by 50% of patients and diabetes-related distress
by 30%.
Although the positive associations between
poorer glycemic control and depression
parameters were observed at baseline for only
two of the three depression parameters (history
of depression diagnosis and diabetes distress),
there was a higher rate of microvascular
complications for all three parameters. While
the mean HbA1c values improved for patients
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during the 24 months following insulin
initiation, glycemic control was poorer for
patients with, compared to without, the
depressive parameters. A higher HbA1c at
baseline is, however, associated with a higher
HbA1c at endpoint after insulin treatment,
although the decrease in HbA1c is higher [48,
49]. A higher HbA1c at baseline was also
associated with higher HbA1c at endpoint in
the TREAT study [44]. In this analysis, insulin
regimens were similar between groups with or
without depressive parameters, and thus a
higher HbA1c at endpoint is not unexpected
and probably more linked to the difficulty and
need of more complex insulin regimens in
patients with worse glycemic control at insulin
initiation than to depressive parameters.
The consistent findings may be due, at least
in part, to the positive and significant
interrelationships between the depression
parameters. Although the correlations were
relatively small in magnitude, the correlation
between diabetes distress and depressed mood
was higher (r = 0.396). This is consistent with
prior research [28], which reported a correlation
of r = 0.48 between depressed mood and
diabetes distress. Therefore, current findings
suggest that the different depression
parameters may capture a different but
interrelated condition that may require
additional assessment and management to
optimize glycemic control in patients with
T2DM.
In addition, the importance of identifying a
history of depression diagnosis has been
highlighted by the finding that patients with a
history of depression diagnosis had higher
levels of depressed mood and diabetes distress
not only at baseline, but also during the follow-
up period. Interestingly, this differentiation
persisted over the 24-month study for diabetes
distress but did not persist for depressed mood
beyond the 12-month assessment. Patients with
or without a history of depression diagnosis no
longer differed on their level of depressed mood
after 12 months of insulin therapy, suggesting
that those with a preexisting depression
diagnosis may have achieved remission, as
their levels of depressive symptoms did not
differ from patients without a history of
depression diagnosis.
This exploratory, post hoc analysis has a
number of potential limitations. First is the
post hoc nature of the analysis, as the TREAT
study was originally designed to assess
glycemic response in T2DM patients initiating
insulin. Another limitation is the proxy nature
of the studied depression parameters. None of
the measures used in the analysis were
developed or validated for use as a stand-
alone measure of depression, thus the
psychometric properties of these depression
parameters for this use are unknown. A third
limitation relates to the history of depression
diagnosis at baseline, which does not offer
information regarding the specific type of
depression diagnosis or when the diagnosis
was made. Moreover, no information was
available on patients’ use of antidepressants at
baseline during the study follow-up period, and
the use of antidepressants would be expected to
impact patients’ level of depression and
anxiety. Furthermore, high versus low
diabetes distress was distinguished by a
threshold score of C75% in the psychological
distress score distribution. We chose this
threshold based on the statistical distribution
and not on any concurrent validation with
other measures of distress.
An additional limitation of the study is that
we conducted analyses using observed data. It is
not possible to rule out that the missing data
312 Diabetes Ther (2015) 6:303–316
(through dropouts and missing visits) show
informative missingness and that the results
may be different if we had complete data on
every subject that entered the study.
The study strengths include the longitudinal
measurement of HbA1c and multiple affective
measures available at six time points over a
24-month period, which enabled the
assessment of both cross-sectional and
longitudinal relationships between glycemic
control and affective parameters. Reported
results reflected adjusted as well as unadjusted
analyses, which helped address a number of
core baseline differences between those with
and without the affective measure. Another
strength is the focus on patients initiating
insulin.
CONCLUSIONS
Current findings of a decline in the proportion
of patients with depressive mood from pre-
initiation to post-initiation of insulin therapy
may suggest that once the barriers associated
with insulin treatment have been addressed,
depressed mood improves with better glycemic
control. A better understanding of the
relationship between glycemic control,
diabetic complications, and specific affective
parameters may help clinicians to focus more
attention on screening for affective conditions
and provide information that may lead to more
timely treatment or referrals to both mental
health and diabetes professionals. In addition to
the potential beneficial impact on clinical
practice and patients’ outcomes, such
information may also be useful for diabetes
research, as it may help highlight the need to
evaluate specific potential affective confounders
when assessing glycemic control among
patients with T2DM, in either cross-sectional
or longitudinal manner.
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